ArticlePharmacotherapy2016
Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.
Article in Pharmacotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.Clinical pharmacology and therapeutics · 2019Pooled it
- Predictor Role ofMedicina (Kaunas, Lithuania) · 2025Article
- Evaluation of supervised machine learning algorithms in predicting the poor anticoagulation control and stable weekly doses of warfarin.International journal of clinical pharmacy · 2023Article
- Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research.Molecular genetics and genomics : MGG · 2022Article
- Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for Geographic and Racial Differences in Stroke Studies.Frontiers in genetics · 2021Article
- Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.Pharmacogenomics and personalized medicine · 2021Article
- Pharmacogenomics for Primary Care: An Overview.Genes · 2020Review
- Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States.Journal of the American Society of Nephrology : JASN · 2020Article
- A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study.Frontiers in pharmacology · 2020Article
- VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People.Clinical and translational science · 2019Article
- Pharmacogenetics of warfarin dosing in patients of African and European ancestry.Pharmacogenomics · 2018Review
- Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Pharmacotherapy · 2018Article
- Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.Molecules (Basel, Switzerland) · 2017Article
- Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Pharmacotherapy · 2017Article
- Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.Pharmacogenetics and genomics · 2017Article
- Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.Pharmacogenomics · 2017Article
- Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.Journal of thrombosis and haemostasis : JTH · 2017Article
- Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.The American journal of medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveThe p.V433M in cytochrome P450 4F2 (rs2108622, CYP4F2*3) is associated with a higher warfarin dose and lower risk of hemorrhage among European Americans. We evaluate the influence of CYP4F2*3 on warfarin dose, time to target international normalized ratio (INR), and stable dose, proportion of time spent in target range (PTTR), as well as the risk of overanticoagulation and hemorrhage among European and African Americans.
designCYP4F2*3 was genotyped in 1238 patients initiated on warfarin in a prospective inception cohort. Multivariable linear regression was used to assess warfarin dose and PTTR; proportional hazards analysis was performed to evaluate time to target INR and stable dose, overanticoagulation, and hemorrhage.
settingTwo outpatient anticoagulation clinics.
participantsA total of 1238 anticoagulated patients. OUTCOMES: Warfarin dose (mg/day), time to target INR and stable dose, PTTR, overanticoagulation (INR more than 4), and major hemorrhage.
resultsMinor allele frequency for the CYP4F2*3 variant was 30.3% among European Americans and 8.4% among African Americans. CYP4F2*3 was associated with higher dose among European Americans but not African Americans. Compared to CYP4F2*1/*1, *1/*3 was associated with a statistically nonsignificant increase in dose (4.5%, p=0.22) and *3/*3 was associated with a statistically significant increase in dose (13.2%, p=0.02). CYP4F2 genotype did not influence time to target INR, time to stable dose, or PTTR in either race group. CYP4F2*3/*3 was associated with a 31% lower risk of over anticoagulation (p=0.06). Incidence of hemorrhage was lower among participants with CYP4F2 *3/*3 compared with *1/*3 or *1/*1 (incidence rate ratio = 0.45, 95% confidence interval 0.14-1.11, p=0.09). After controlling for covariates, CYP4F2 *3/*3 was associated with a 52% lower risk of hemorrhage, although this was not statistically significant (p=0.24).
conclusionPossession of CYP4F2*3 variant influences warfarin dose among European Americans but not African Americans. The CYP4F2-dose, CYP4F2-overanticoagulation, and CYP4F2-hemorrhage association follows a recessive pattern with possession of CYP4F2*3/*3 genotype likely demonstrating a protective effect. These findings need further confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.